...
机译:使用护理点生物标志物对疗效体外膜氧合疗法患者医院存活预后模型的开发和外部验证:预测 - VA-ECMO评分
Department of Cardiology and Angiology I University Heart Center Freiburg – Bad Krozingen;
Department of Cardiology and Angiology I University Heart Center Freiburg – Bad Krozingen;
Institute for Medical Biometry and Statistics Faculty of Medicine and Medical Center – University;
Institute for Medical Biometry and Statistics Faculty of Medicine and Medical Center – University;
Department of Cardiovascular Surgery University Heart Center Freiburg;
Department of Cardiology and Angiology I University Heart Center Freiburg – Bad Krozingen;
Department of Cardiothoracic Surgery University Hospital Regensburg;
Department of Internal Medicine II University Hospital Regensburg;
Department of Cardiology and Angiology I University Heart Center Freiburg – Bad Krozingen;
Department of Cardiology and Angiology I University Heart Center Freiburg – Bad Krozingen;
机译:使用护理点生物标志物对疗效体外膜氧合疗法患者医院存活预后模型的开发和外部验证:预测 - VA-ECMO评分
机译:一项用于评估严重成人呼吸窘迫综合征患者接受体外膜氧合治疗的生存率的评分的外部验证:一项回顾性研究
机译:使用血液生物标志物信息开发和验证预后模型,以预测单独接受化学疗法和放疗或放疗联合治疗的非小细胞肺癌患者的生存(NCT00181519,NCT00573040和NCT00572325)。
机译:弥漫性大B细胞淋巴瘤化疗后患者生存的预后生物标志物:88例回顾性分析
机译:一项用于评估严重成人呼吸窘迫综合征患者接受体外膜氧合治疗的生存率的评分的外部验证:一项回顾性研究
机译:静脉室体外膜氧合治疗患者存活模型的开发与验证:预测VA-ECMO评分